Illumina, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Illumina, Inc. is a global life sciences company specializing in developing, manufacturing, and marketing integrated systems and tools for genetic and genomic analysis. Its core products and services include next-generation sequencing (NGS) platforms such as the NovaSeq X series; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; gene expression analysis; genotyping solutions; and multiomics applications including genome sequencing, copy number variation (CNV) analysis, and DNA methylation profiling. Illumina also provides molecular diagnostic products and services, including comprehensive genomic profiling tests for oncology, and offers instrument services, training, and consulting. The company serves a broad customer base comprising genomic research institutes, clinical research organizations, pharmaceutical and biotechnology companies, and governmental laboratories across the Americas, Europe, Greater China, Asia Pacific, Middle East, and Africa. Founded in 1998, Illumina is headquartered in San Diego, California. In the last 1-2 years, Illumina has made significant strategic advancements to expand its technological and commercial footprint. In 2025, Illumina launched BioInsight, a new business unit focused on combining sequencing, data analysis, software, and artificial intelligence to enable deeper biological insights for pharmaceutical research, drug target identification, and novel disease mechanisms discovery. Additionally, Illumina completed the acquisition of SomaLogic, a leader in data-driven proteomics, enhancing its multiomics strategy by integrating SomaLogic's aptamer-based proteomics platform to drive advanced biomarker discovery and disease profiling. Illumina further expanded its personalized cancer care efforts through new partnerships with global pharmaceutical companies to develop companion diagnostics enabled by its TruSight Oncology Comprehensive genomic profiling test. The company also introduced innovative technologies such as a 5-base sequencing solution for simultaneous genomic and epigenomic insights and Constellation mapped read technology to detect complex genomic variants. Illumina operates primarily through two segments: Core Illumina, which encompasses life sciences and genomics research products, and GRAIL, focusing on early cancer detection technologies. The company's continued investments in advanced sequencing technology, data analytics, AI-driven discovery, and multiomics integration reinforce its leadership position in genomics and molecular diagnostics worldwide.
Company News
Why Moderna's Cancer Vaccine Matters to Investors
Should You Add Illumina Stock to Your Portfolio Now?
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
Biondo Investment Advisors LLC Takes $1.87 Million Position in Illumina, Inc. $ILMN
Allworth Financial LP Purchases New Position in Illumina, Inc. $ILMN
Illumina, Inc. Post Earnings: Buy On A Pullback
BMRN vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?
Empowered Funds LLC Increases Stock Holdings in Illumina, Inc. $ILMN
What Makes Illumina (ILMN) a New Strong Buy Stock
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Illumina, Inc. (ILMN) Hits Fresh High: Is There Still Room to Run?
Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say
Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
Insights Into Illumina (ILMN) Q2: Wall Street Projections for Key Metrics
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown